Full Press Release Details
Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL's International Liver Congress (ILC) 2022.
SGMT
Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL's International Liver Congress (ILC) 2022
Key Takeaway: Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL's International Liver Congress (ILC) 2022